Emerging Therapies for HER2 Positive Breast Cancer

Synopsis:

HER2 targeted therapies have had a significant impact in improving clinical outcomes and survival for patients with HER2 positive breast cancer. However, new therapies for patients with refractory disease are still needed. Based on a greater understanding of the biology and mechanisms of resistance, a new generation of HER2 agents is evolving. Here we provide an overview of promising novel therapies, both proven and in development, for the treatment of refractory HER2 positive breast cancer. This will include a review of antibody drug conjugates, tyrosine kinase inhibitors, immune strategies as well as future combination therapies.